590
A. Vinothkanna and S. Sekar
Table 24.1 (continued)
Disease/diagnostic parameters
Patents-source/country and number
Risk of preterm births
IN 679/MUMNP/2012
Premature rupture of fetal membrane
CN103267851 (E)
Fetal cells in maternal blood
US 5766843, US 5858649, US 5861253,
IN 9840/DELNP/2015
Testicular spermatogenic function
CN107315092 (E)
(G) Miscellaneous issues
Transplantation—MHC (Major
Histocompatibility Complex) allo antibody
testing for irreversible or terminal organ failure
IN 201811016151
Numerical chromosomal
abnormalities—aneuploidy and polyploidy
IN 993/DELNP/2004
Detection of fish allergen—parvalbumin
CN102680674 (E)
Detection of insulin sensitivity enhancers
US 5466610
Exposure/immunity to dengue virus
IN 4605/KOLNP/2010
Abbreviations: AU—AusPat database, Australia; CN—CNIPA database, China; (E)—Espacenet
database, European Patent Office; IN—InPASS database, India; JP—J-Plat Pat database, Japan;
KR—KIPRIS database, Korea; US—USPTO database, United States of America
Patent numbers represent application numbers except numbers with prefix “CN” and suffix “(E)”
that denote publication numbers. Except Espacenet, numbers alone (without prefix alphabets) have
to be entered in the suitable search field of the corresponding country’s database. Such prefix
alphabets are meant for identifying the database. In Espacenet alone (tagged with “(E)” as suffix
of numbers), given alphabetic prefix along with the publication numbers have to be fed to access
patent details
Immunotyping of human papillomavirus using monoclonal antibody bound phycoerythrin in the form of luminex microsphere employing multiplexed assay system
was developed (Opalka et al. 2003). Monitoring the efficacy of drug, anti-retroviral
therapy (ART) in human immunodeficiency virus (HIV) patients was performed
using phycoerythrin and fluorescein isothiocyanate (FITC) conjugated anti-CD38
monoclonal antibodies (Onlamoon et al. 2011).
However, the major exploitation of PBPs for such of these diagnostics resides in
patents (Table 24.2). There were patents covering the diagnosis of any pathogenesis
in human body by analyzing suitable marker proteins and inflammatory responses.
Similarly, diagnosis of diseases caused by many bacterial pathogens and their toxins
along with some fungal pathogens employing suitable antigens as markers for detection was performed. However, an array of viral diagnostics were prevalent among
patents. Additionally, diagnosis of a group/combination of bacterial, fungal and viral
pathogens, parasitic worms, and prions were also patented (Table 24.2).
A. Vinothkanna and S. Sekar
Table 24.1 (continued)
Disease/diagnostic parameters
Patents-source/country and number
Risk of preterm births
IN 679/MUMNP/2012
Premature rupture of fetal membrane
CN103267851 (E)
Fetal cells in maternal blood
US 5766843, US 5858649, US 5861253,
IN 9840/DELNP/2015
Testicular spermatogenic function
CN107315092 (E)
(G) Miscellaneous issues
Transplantation—MHC (Major
Histocompatibility Complex) allo antibody
testing for irreversible or terminal organ failure
IN 201811016151
Numerical chromosomal
abnormalities—aneuploidy and polyploidy
IN 993/DELNP/2004
Detection of fish allergen—parvalbumin
CN102680674 (E)
Detection of insulin sensitivity enhancers
US 5466610
Exposure/immunity to dengue virus
IN 4605/KOLNP/2010
Abbreviations: AU—AusPat database, Australia; CN—CNIPA database, China; (E)—Espacenet
database, European Patent Office; IN—InPASS database, India; JP—J-Plat Pat database, Japan;
KR—KIPRIS database, Korea; US—USPTO database, United States of America
Patent numbers represent application numbers except numbers with prefix “CN” and suffix “(E)”
that denote publication numbers. Except Espacenet, numbers alone (without prefix alphabets) have
to be entered in the suitable search field of the corresponding country’s database. Such prefix
alphabets are meant for identifying the database. In Espacenet alone (tagged with “(E)” as suffix
of numbers), given alphabetic prefix along with the publication numbers have to be fed to access
patent details
Immunotyping of human papillomavirus using monoclonal antibody bound phycoerythrin in the form of luminex microsphere employing multiplexed assay system
was developed (Opalka et al. 2003). Monitoring the efficacy of drug, anti-retroviral
therapy (ART) in human immunodeficiency virus (HIV) patients was performed
using phycoerythrin and fluorescein isothiocyanate (FITC) conjugated anti-CD38
monoclonal antibodies (Onlamoon et al. 2011).
However, the major exploitation of PBPs for such of these diagnostics resides in
patents (Table 24.2). There were patents covering the diagnosis of any pathogenesis
in human body by analyzing suitable marker proteins and inflammatory responses.
Similarly, diagnosis of diseases caused by many bacterial pathogens and their toxins
along with some fungal pathogens employing suitable antigens as markers for detection was performed. However, an array of viral diagnostics were prevalent among
patents. Additionally, diagnosis of a group/combination of bacterial, fungal and viral
pathogens, parasitic worms, and prions were also patented (Table 24.2).